Compare FLNG & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNG | SRPT |
|---|---|---|
| Founded | 2006 | 1980 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2019 | 2000 |
| Metric | FLNG | SRPT |
|---|---|---|
| Price | $30.66 | $15.77 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 29 |
| Target Price | $23.00 | ★ $25.85 |
| AVG Volume (30 Days) | 376.6K | ★ 3.6M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 9.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.14 | N/A |
| P/E Ratio | $19.72 | ★ $5.51 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $23.66 | $11.68 |
| 52 Week High | $33.40 | $25.32 |
| Indicator | FLNG | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 35.98 |
| Support Level | $30.60 | $15.55 |
| Resistance Level | $31.31 | $18.16 |
| Average True Range (ATR) | 0.83 | 0.93 |
| MACD | 0.10 | -0.35 |
| Stochastic Oscillator | 62.63 | 5.96 |
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.